Enoblituzumab (MGA271): An Investigational Anti-B7-H3 Monoclonal Antibody - Comprehensive Review

1. Introduction to Enoblituzumab (MGA271)

Enoblituzumab, also known by its investigational designation MGA271, is a humanized IgG1κ monoclonal antibody that has been developed as an immunotherapeutic agent targeting various forms of cancer.[1] As an investigational drug, it has been the subject of numerous clinical trials to evaluate its safety and efficacy.[3] The primary molecular target of enoblituzumab is B7-H3 (CD276), a transmembrane protein frequently overexpressed on the surface of a diverse array of tumor cells and often associated with a poor prognosis.[2] A distinguishing feature of enoblituzumab is its engineered fragment crystallizable (Fc) domain, a modification intended to significantly enhance its immune effector functions.[7] This Fc-optimization is a core element of its design by MacroGenics, aimed at improving its therapeutic potential compared to standard antibodies by augmenting its ability to trigger an immune response against cancer cells.

Key Identifiers and Properties:

Enoblituzumab is classified as a biotech therapeutic, specifically a monoclonal antibody.[3] Its Chemical Abstracts Service (CAS) Number is 1353485-38-7, and its DrugBank accession number is DB15017.[1] Alternative designations used in research and development include MGA271, MGA-271, TJ271, and TJ-271.[1] The Unique Ingredient Identifier (UNII) for enoblituzumab is M6030H73N9.[3]

Chemically and physically, enoblituzumab is a humanized IgG1κ monoclonal antibody with a molecular weight of approximately 146.1 kDa.[1] It is typically produced in Chinese Hamster Ovary (CHO) cells and purified using methods such as Protein A chromatography.[1] It is formulated as a liquid for administration and recommended for storage at -80°C.[1] Enoblituzumab is designed to be reactive with human B7-H3.[1]